Who is responsible for prosecuting cannabis in Slovenia?

There is still no official translation of the 1961 Convention, but the Ministry of Health is commissioning a study on other countries

In April, The National Assembly Health Committee called on the ministry to prepare the grounds for cannabis cultivation by the end of this year.

Where is the sticking point?

The Ministry of Health has announced a low-value study for analyzing the costs and benefits of regulating cannabis cultivation for medical purposes in Slovenia, while SD representative Bojana Muršič is asking Minister Minister Aleš Šabeder for the purpose, as all the explanations have been gathered in 2016. Members of Parliament have been misled for years.

The analysis should include an overview of cannabis cultivation regimes for medical purposes in the EU countries, identifying the varieties of cannabis that are most in demand on the market, as well as the presentation and dissemination of the results, which will take a year. It won’t be cheap; providers must prove they have completed at least two comparable health surveys worth at least € 25,000 in five years.

All these years, the officials of the ministry you lead ensure that the risks and costs outweigh the benefits that are minimal. In a public debate that has intensified in recent years, on a number of occasions from a number of different sources the ministry has been presented credible information, publicly and clearly, which they want to collect now through the public procurement and (re)use of public funds“, Muršič warns the minister and adds that in April, the National Assembly Health Committee called on the ministry to prepare the grounds for cannabis
cultivation by the end of this year.

cannabis
Photo: Voranc Vogel/Delo

The Convention does not classify hemp plants as illicit drugs; that is a Slovenian particularity that was added by an unofficial translation from ten years ago.

Confusion due to wrong translation

Even in the order, the ministry points out that the regulation on hemp use in our country is based on three UN conventions, first a single drug convention of 1961 and related protocols of 1972. “The basis for the classification of the cannabis plant as well as the resin in the illicit drug list is thus the Single Convention as well as the 1988 Convention on Illicit Traffic in Narcotic Drugs and Psychotropic Substances. The Single Convention allows the cultivation of cannabis for medical purposes under certain conditions”, the ministry writes.

But here’s the catch. The Convention does not classify hemp plants as llicit drugs; that is a Slovenian particularity that was added with an unofficial translation from ten years ago. Exactly three years ago, this translation of the convention was removed from the websites of all bodies, including the Ministry of Justice. Thus, Slovenia does not have an official translation of the convention, thus violating said convention. Even worse, this unofficial translation is still used by the courts and police in criminal proceedings.

cannabis
Photo: Roman Šipić/Delo

According to the Rules of Procedure, the Drugs Commission should operate in the Slovenian language, which is not easy when the Single convention is available in Serbian and French, since Slovenia succeeded it from Yugoslavia.

Who is responsible?

Responsibility for the professional preparation and coherence of the material, which appears everywhere from the government commission to the World Health Organization (WHO) regional organization, is in the Health promotion and control of chronic non-communicable diseases and conditions department of the Ministry of Health.

Author: Borut Tavčar, Delo

 

Members of the European Parliament recommended: Take medical use of cannabis seriously

Members of the European Parliament (MEP) proposed the ways to address research gaps on medical cannabis and call on member states to seize the potential of cannabis-based medicines.

In a resolution adopted on Wednesday 11 September, MEPs call on the Commission and national authorities to draw a clear distinction between medical cannabis and other uses of cannabis. The resolution urges the Commission and member states to address regulatory, financial and cultural barriers which burden scientific research and invites them to properly fund research. The EU should embark on more research and stimulate innovation with regard to medicinal cannabis projects.

MEPs call on member states to allow doctors to use their professional judgement in prescribing cannabis-based medicines. When effective, these medicines are to be covered by health insurance schemes in the same way as other types of medicine, they say.

European Parliament

The regulation of cannabis-based medicines would translate into additional revenue for public authorities, would limit the black market and ensure quality and accurate labelling. It would also limit minors’ access to this substance, they say.

MEPs say that there is evidence that cannabis or cannabinoids may be effective in increasing appetite and decreasing weight loss associated with HIV/AIDS. Medical cannabis may also help to alleviate the symptoms of mental disorders such as psychosis or Tourette syndrome, and to alleviate the symptoms of epilepsy, as well as Alzheimer’s, arthritis, asthma, cancer, Crohn’s disease and glaucoma. They also help to reduce the risk of obesity and diabetes and ease menstrual pain.

Whilst the WHO has officially recommended that the cannabis compound cannabidiol (CBD) should not be classified as a controlled substance, legislation in member states differs widely on the subject of cannabis for medicinal purposes.

The European Parliament is made up of 751 Members elected in the 28 Member States of the enlarged European Union. Since 1979 MEPs have been elected by direct universal suffrage for a five-year period.

Research Publication on the Effectiveness of Cannabinoids on Glioblastoma

Slovenian National Institute of Biology and University Medical Centre Ljubljana, with MGC Pharma Research and Development Division, conducted the study about the treatment of high-grade brain tumours, i.e. glioblastoma with cannabinoids. The general aim of the research was to develop formulations to define the protocols for the treatment.

Study evaluated cannabinoid receptor proteins that may add to identify the most effective cytotoxic cannabinoids, known so far, e.g. CBD and THC ratios and further their possible synergistic effects with chemotherapeutic Temozolomide (‘TMZ’) with regards to the treatment of glioblastoma patients.

Conclusions of the study

Cannabinoids, especially at increasing THC concentrations, reduce the viability of glioblastoma cells.

Targeting glioblastoma stem cells (GSCs) that are more resistant to chemotherapy. GSC has so far proved to be more vulnerable to cannabinoids than were differentiated cell (publication in preparation).

At optimal concentration for each patient, the defined cannabinoids composition represents promising tool to reduce tumour burden.

Research collaboration is part of MGC Pharma’s strategy of partnering with leading research institutions to examine opportunities to develop new pharma products based on proven cannabinoid formulations in pre-and clinical studies.

The study results can be viewed on the Company’s website and will be presented by the National Institute of Biology at the 2nd International Annual Congress on Controversies on Cannabis-Based Medicines in Barcelona, Spain on 23-24 May 2019.